Aura Biosciences Stock

aurabiosciences.comBioTechFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Aura Biosciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Julie Feder
Chief Financial Officer
Andrew Russell Ph.D
Director, Manufacturing
Cadmus Rich MD
Chief Medical Officer
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Stephen Monks Ph.D
Senior Vice President, Development
Michele Keough
Senior Vice President, R&D Operations
Richard Peters Ph.D
Advisor
Alan Walts Ph.D
Executive Chairman

Board Members

Alan Walts Ph.D
Arthur Pappas
Chiesi Ventures
Casper Breum
Lundbeckfonden
Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Giovanni Mariggi Ph.D
Medicxi
Henri Termeer
Israel Ruiz
Javier García
Columbus Venture Partners
Joël Jean-Mairet Ph.D
Ysios Capital
Mark Chin
Arix Bioscience
Rajesh Parekh Ph.D
Advent Life Sciences
Salvador Garcia-Atance Ph.D

Other companies like Aura Biosciences in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum